J Cancer
2011; 2:339-340.
doi:10.7150/jca.2.339 This volumeCite
Short Report
Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft
Fabio Ciceri, Marco Bregni, Jacopo Peccatori✉
Hematology and BMT Unit, Department of Oncology, San Raffaele Scientific Institute, Milano, Italy
✉ Corresponding author: Fabio Ciceri MD, San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milano, Italy. Phone +39 02 2643 3903; Fax +39 02 2643 4760; email: fabio.ciceriit
Citation:
Ciceri F, Bregni M, Peccatori J. Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft. J Cancer 2011; 2:339-340. doi:10.7150/jca.2.339. https://www.jcancer.org/v02p0339.htm
We exploited the dual positive effects of rapamycin to prevent GvHD and control malignant cells upon infusion of unmanipulated grafts from family haploidentical donors to patients affected by advanced hematological malignancies. Preliminary results on 45 patients show the feasibility of this platform with an appreciable low rate of GvHD.
Ciceri, F., Bregni, M., Peccatori, J. (2011). Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft. Journal of Cancer, 2, 339-340. https://doi.org/10.7150/jca.2.339.
ACS
Ciceri, F.; Bregni, M.; Peccatori, J. Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft. J. Cancer 2011, 2, 339-340. DOI: 10.7150/jca.2.339.
NLM
Ciceri F, Bregni M, Peccatori J. Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft. J Cancer 2011; 2:339-340. doi:10.7150/jca.2.339. https://www.jcancer.org/v02p0339.htm
CSE
Ciceri F, Bregni M, Peccatori J. 2011. Innovative Platforms for Haploidentical Stem Cell Transplantation: The Role of Unmanipulated Donor Graft. J Cancer. 2:339-340.